Cardinal Health 414 patents expiration
1. Lymphoseek Kit patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6409990 | CARDINAL HEALTH 414 | Macromolecular carrier for drug and diagnostic agent delivery |
May, 2025
(1 year, 14 days from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9439985 | CARDINAL HEALTH 414 | Compositions for radiolabeling diethylenetriaminepentaacetic acid (DTPA)-dextran |
Jan, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | May 19, 2024 |
| New Indication(I-687) | Jun 13, 2017 |
| Orphan Drug Exclusivity(ODE) | Jun 13, 2021 |
| Orphan Drug Exclusivity(ODE-67) | Jun 13, 2021 |
| New Chemical Entity Exclusivity(NCE) | Mar 13, 2018 |
Drugs and Companies using TECHNETIUM TC-99M TILMANOCEPT ingredient
NCE-1 date: 13 March, 2017
Market Authorisation Date: 13 March, 2013
Treatment: NA
Dosage: INJECTABLE;INJECTION
More Information on Dosage
LYMPHOSEEK KIT family patents
